393 related articles for article (PubMed ID: 21098338)
1. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
2. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
3. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
5. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
6. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.
Song N; Liu S; Zhang J; Liu J; Xu L; Liu Y; Qu X
Int J Mol Sci; 2014 Apr; 15(4):5838-51. PubMed ID: 24714091
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.
Jones VT; Graves-Deal R; Cao Z; Bogatcheva G; Ramirez MA; Harmych SJ; Higginbotham JN; Sharma V; Damalanka VC; Wahoski CC; Joshi N; Irudayam MJ; Roland JT; Ayers GD; Liu Q; Coffey RJ; Janetka JW; Singh B
Cell Mol Life Sci; 2024 Jan; 81(1):28. PubMed ID: 38212428
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
13. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
[TBL] [Abstract][Full Text] [Related]
14. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Myers MV; Manning HC; Coffey RJ; Liebler DC
Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
[TBL] [Abstract][Full Text] [Related]
15. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
Yang L; Li J; Ran L; Pan F; Zhao X; Ding Z; Chen Y; Peng Q; Liang H
J Gastrointest Surg; 2011 Jun; 15(6):942-57. PubMed ID: 21479670
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
18. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
19. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
20. SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer.
Piao HY; Qu JL; Liu YP
Cancer Chemother Pharmacol; 2022 Apr; 89(4):441-449. PubMed ID: 35195773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
